Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $20.89 Consensus Target Price from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have earned an average recommendation of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $20.89.

Several equities analysts have issued reports on the company. Wedbush reiterated an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Friday. Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. Oppenheimer initiated coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Wednesday, December 11th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Massachusetts Financial Services Co. MA lifted its stake in Y-mAbs Therapeutics by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock valued at $993,000 after buying an additional 2,760 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Y-mAbs Therapeutics by 10.4% in the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock valued at $399,000 after acquiring an additional 2,854 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at $44,000. China Universal Asset Management Co. Ltd. increased its position in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after purchasing an additional 3,416 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its position in Y-mAbs Therapeutics by 4.2% during the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock worth $1,084,000 after purchasing an additional 3,589 shares in the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB opened at $6.89 on Friday. Y-mAbs Therapeutics has a 1 year low of $6.84 and a 1 year high of $20.90. The stock has a market capitalization of $308.60 million, a P/E ratio of -12.76 and a beta of 0.69. The company’s fifty day moving average is $10.32 and its two-hundred day moving average is $12.13.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the firm earned ($0.18) earnings per share. Sell-side analysts predict that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.